Skip to content
Medical Health Aged Care

Parse Biosciences Launches Certified Service Provider Program

Parse Biosciences 2 mins read

Eurofins Clinical Enterprise, LLC and SeqMatic first providers to join program, expanding access to Parse’s growing single cell portfolio


SEATTLE--BUSINESS WIRE--

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of its Certified Service Provider (CSP) Program. For researchers who are seeking paths to outsource their single cell projects, Parse’s CSP Program provides options to partner with trusted service providers capable of running smaller pilot projects up to performing routine high throughput projects.

Fremont, California-based SeqMatic and Framingham, Massachusetts-based Eurofins Clinical Enterprise, LLC are the first CSPs to partner with Parse to offer its expanding portfolio of single cell products, including its Evercode™ Whole Transcriptome, Evercode™ TCR, CRISPR Detect, Gene Capture, and its recently released Evercode™ BCR, which captures full length BCR sequences and gene expression together at unprecedented scale.

“The advances we’re seeing as a result of single cell sequencing continue to transform scientific research,” noted Parse co-founder and CEO Alex Rosenberg. “The CSP Program is an important step in broadening access to scalable single cell sequencing, and we’re proud to have SeqMatic and Eurofins Clinical Enterprise join us as our first partners in this initiative.”

Comprehensive CSPs providing a full range of high quality end-to-end multi omics workflow solutions including DNA and RNA sequencing, SeqMatic and Eurofins Clinical Enterprise can manage samples from any US or international location, including multi-site collaborations and unique requirements. Their professional service provides assurance of expert handling, tracking and coordination of samples.

“SeqMatic is dedicated to providing the highest level of service and cutting edge technologies to our more than 700 customers in the US and around the world,” said SeqMatic CEO Len Goren. “We are excited to make Parse’s industry-leading single cell sequencing kits available to all of them.”

Partner companies like SeqMatic and Eurofins Clinical Enterprise that offer Parse’s kits as a service must meet Parse’s stringent criteria and provide the highest quality results to their clients. For more information about Parse’s CSP program, visit https://www.parsebiosciences.com/service-providers/. To learn more about SeqMatic’s Parse offerings, visit https://www.seqmatic.com/services/parse-biosciences-single-cell-rna-sequencing-service/, and to learn more about Eurofins Clinical Enterprise’s Parse offerings, visit https://clinicalenterprise.com/.

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach is enabling groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

Founded based on a transformative technology invented at the University of Washington, Parse has raised over $100 million and is used in nearly 2,000 labs across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for data analysis.

Headquartered in Seattle, Washington’s vibrant South Lake Union district, Parse Biosciences recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.


Contact details:

Jay Roberts, SRPR
jay@shevrushpr.com | 917.696.2142

Media

More from this category

  • Community, Medical Health Aged Care
  • 22/07/2024
  • 17:24
Odyssey Lifestyle Care Communities

Dancing and dining; seniors celebrate four fabulous years

Odyssey Lifestyle Care Communities recently celebrated a significant milestone in style, marking its fourth birthday with an evening full of fun, fantastic food and…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56
Illumina

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:
  • Industrial Relations, Medical Health Aged Care
  • 22/07/2024
  • 11:12
Australian Nursing and Midwifery Federation (Victorian Branch)

Bolton Clarke nurses and carers to hold stop-work rally – Mon 22 July, 1pm-2pm

WHATANMF Bolton Clarke members two-hour stop work and community rally for fair pay and conditionsACTU Secretary Sally McManus and VTHC Secretary Luke Hilakari will address the rally WHENMonday, 22 July 2024, 1pm-3pm. (Speakers will start 1.05pm sharp) WHEREoutside Bolton Clarke’s Victorian headquarters, 347 Burwood Highway, Forest Hill Bolton Clarke nurses, personal care workers and midwives will stop work for two hours on Monday 22 July to rally for better pay and conditions. For the past 18 months, the Australian Nursing and Midwifery Federation (Victorian Branch) has been negotiating wages and conditions on behalf of about 1700 members working across Bolton…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.